Elraglusib

N/A

Report date: 2025/01/09 17:37:01
NME

Base Information

Drug NameElraglusib
Drug Alias Name9-ING-41
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 beta
Therapy Area/IndicationsBone metastasesPrimary MyelofibrosisNeoplasm Metastasis +[30] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Illinois At ChicagoNorthwest UniversityActuate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of IllinoisActuate Therapeutics IncNorthwestern University
Inactive CompaniesBrown University
Active IndicationsBone metastasesPrimary MyelofibrosisNeoplasm Metastasis +[16] 
Inactive IndicationsBrain NeoplasmsMeningiomaNeuroblastoma +[14] 

Other Information

ATC CodeN/A
Related LinksN/A